(2-methylphenyl)(4'-chlorophenyl)methanol | 29338-51-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2-methylphenyl)(4'-chlorophenyl)methanol
• 英文别名: (4-chlorophenyl)(o-tolyl)methanol；2-methyl-4'-chlorobenzhydrol；p-Chlorphenyl-(o-tolyl)-methanol；(4-chlorophenyl)-(2-methylphenyl)methanol
• CAS: 29338-51-0
• 化学式: C₁₄H₁₃ClO
• mdl: MFCD11097018
• 分子量: 232.71
• InChiKey: QWNMGIKDLZTPOI-UHFFFAOYSA-N

物化性质

• 沸点：
  369.6±32.0 °C(Predicted)
• 密度：
  1.191±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (2-methylphenyl)(4'-chlorophenyl)methanol 在 lithium aluminium tetrahydride 、 三氯化铝 作用下， 以 乙醚 为溶剂， 生成 1-氯-4-(2-甲基苄基)苯
  参考文献：
  名称：

  Blackwell,J.; Hickinbottom,W.J., Journal of the Chemical Society, 1961, p. 1405 - 1407

  摘要：

  DOI：
• 作为产物：
  描述：

  di-o-tolylzinc 在 Cp₂Fe 作用下， 以 四氢呋喃 、 氘代四氢呋喃 、 重水 为溶剂， 生成 (2-methylphenyl)(4'-chlorophenyl)methanol
  参考文献：
  名称：

  醛插入铑-芳基和-醇盐配合物的直接观察

  摘要：

  分离出几种通式 (PPh(3))(2)(CO)RhR (R = p-tolyl, o-tolyl, Me) 的有机铑 (I) 配合物，并显示将芳基醛插入芳基-铑（一）债券。在非水条件下，这些反应以良好的收率提供酮。芳基铑 (I) 配合物的稳定性使这些反应也可以在 THF 和水的混合物中进行。在该溶剂系统中，仅生成二芳基甲醇。机理研究支持通过将醛插入铑-芳基键并随后β-氢化物消除或水解形成二芳基酮或二芳基甲醇产物来形成酮和二芳基甲醇。THF/水混合物中的动力学同位素效应和二芳基甲醇的形成与酰基碳氢键的氧化加成和还原消除形成酮不一致。此外，在反应过程中直接观察到由醛插入形成的中间体二芳基甲醇铑。其结构由独立合成证实。该复合物经过β-氢消除以形成酮。该醇盐还与第二个醛反应，通过插入和随后的β-氢消除形成酯。因此，芳铑配合物与过量醛的反应通过双插入和β-氢消除序列形成酯。其结构由独立合成证实。该复

  DOI：

  10.1021/ja017401e

文献信息

• [EN] AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDRS<br/>[FR] DERIVES AZETIDINECARBOXAMIDE ET LEUR UTILISATION POUR LE TRAITEMENT DE TROUBLES A MEDIATION DU RECEPTEUR DU CB1
  申请人：VERNALIS RES LTD

  公开号：WO2004096794A1

  公开（公告）日：2004-11-11

  Compounds of formula (I) and their use in therapy, particularly for the treatment of a disorder mediated by CB1 receptors, such as obesity, wherein: R1 is aryl or heteroaryl; R2 is alkyl, aryl or heteroaryl; R3 is alkyl, aryl, heteroaryl, NR9R10, OR 15, or NR 16C(O)R17; Y is C=O, C=S, SO2, or (CR7R8)p; m = 1 or 2; n = 1 or 2; and p=1,2,3 or 4, R7 to R17 being as defined in the specification; wherein if -Y-R3 is -C(O)NH(alkyl) then: R1 and/or R2 is selected from heteroary1; and/or m and/or n is 2; and/or R11 and/or R12 is lower alkyl, or a pharmaceutically acceptable salt or prodrug thereof.

  化合物的化学式（I）及其在治疗中的应用，特别是用于治疗由CB1受体介导的疾病，如肥胖，其中：R1为芳基或杂环芳基；R2为烷基，芳基或杂环芳基；R3为烷基，芳基，杂环芳基，NR9R10，OR 15，或NR 16C(O)R17；Y为C=O，C=S，SO2，或（CR7R8）p；m = 1或2；n = 1或2；p=1,2,3或4，R7到R17如规范中定义；其中如果-Y-R3为-C(O)NH(烷基)则：R1和/或R2从杂芳基中选择；和/或m和/或n为2；和/或R11和/或R12为较低烷基，或其药用盐或前药。
• Highly Efficient and Facile Aryl Transfer to Aldehydes Using ArB(OH)2-GaMe3
  作者：Chengjian Zhu、Xuefeng Jia、Ling Fang、Aijun Lin、Yi Pan

  DOI：10.1055/s-0028-1087552

  日期：2009.2

  A rapid and efficient procedure for the synthesis of di­arylmethanols has successfully been achieved by the aryl transfer to aldehydes using the ArB(OH)2-GaMe3 combined systems in excellent yields (up to 98%) at room temperature.

  利用 ArB(OH)2-GaMe3 组合体系，通过芳基转移到醛的方法，成功地实现了一种快速高效的二芳基甲醇合成方法，并在室温下获得了极好的收率（高达 98%）。
• Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disordrs
  申请人：Davidson Edward Paul James

  公开号：US20070173486A1

  公开（公告）日：2007-07-26

  Compounds of formula (I) and their use in therapy, particularly for the treatment of a disorder mediated by CB 1 receptors, such as obesity, wherein: R 1 is aryl or heteroaryl; R 2 is alkyl, aryl or heteroaryl; R 3 is alkyl, aryl, heteroaryl, NR 9 R 10 , OR 15 , or NR 16 C(O)R 17 ; Y is C═O, C═S, SO 2 , or (CR 7 R 8 ); m=1 or 2; n=1 or 2; and p=1, 2, 3 or 4, R 7 to R 17 being as defined in the specification; wherein if —Y—R 3 is —C(O)NH(alkyl) then: R 1 and/or R 2 is selected from heteroaryl; and/or m and/or n is 2; and/or R 11 and/or R 12 is lower alkyl, or a pharmaceutically acceptable salt or prodrug thereof.

  式(I)的化合物及其在治疗中的用途，特别是用于治疗由CB1受体介导的疾病，例如肥胖症，其中：R1为芳基或杂环芳基；R2为烷基，芳基或杂环芳基；R3为烷基，芳基，杂环芳基，NR9R10，OR15或NR16C（O）R17；Y为C═O，C═S，SO2或（CR7R8）；m=1或2；n=1或2；p=1、2、3或4，R7到R17如规范所定义；如果—Y—R3为—C（O）NH（烷基），则：R1和/或R2选自杂环芳基；和/或m和/或n为2；和/或R11和/或R12为较低的烷基，或其药学上可接受的盐或前药。
• Azetidinecarboxamide Derivatives And Their Use In The Treatment Of CB1 Receptor Mediated Disorders
  申请人：Davidson James Edward Paul

  公开号：US20090181939A1

  公开（公告）日：2009-07-16

  Compounds of formula (I) and their use in therapy, particularly for the treatment of a disorder mediated by CB 1 receptors, such as obesity, wherein: R 1 is aryl or heteroaryl; R 2 is alkyl, aryl or heteroaryl; R 3 is alkyl, aryl, heteroaryl, NR 9 R 10 , OR 15 , or NR 16 C(O)R 17 ; Y is C═O, C═S, SO 2 , or (CR 7 R 8 ) p ; m=1 or 2; n=1 or 2; and p=1, 2, 3 or 4, R 7 to R 17 being as defined in the specification; wherein if —Y—R 3 is C(O)NH(alkyl) then: R 1 and/or R 2 is selected from heteroaryl; and/or m and/or n is 2; and/or R 11 and/or R 12 is lower alkyl, or a pharmaceutically acceptable salt or prodrug thereof.

  公式（I）的化合物及其在治疗中的应用，特别是用于治疗由CB1受体介导的疾病，如肥胖症，其中：R1为芳基或杂环芳基；R2为烷基，芳基或杂环芳基；R3为烷基，芳基，杂环芳基，NR9R10，OR15或NR16C（O）R17；Y为C═O，C═S，SO2或（CR7R8）p；m=1或2；n=1或2；p=1、2、3或4，R7至R17如规范中所定义；其中，如果—Y—R3为C（O）NH（烷基），则：R1和/或R2选择自杂环芳基；和/或m和/或n为2；和/或R11和/或R12为低碳烷基，或其药学上可接受的盐或前药。
• Design, synthesis and biological evaluation of piperazine analogues as CB1 cannabinoid receptor ligands
  作者：Kwang-Seop Song、Sung-Han Lee、Hyun Ji Chun、Jong Yup Kim、Myung Eun Jung、Kwangwoo Ahn、Soo-Un Kim、Jeongmin Kim、Jinhwa Lee

  DOI：10.1016/j.bmc.2008.01.023

  日期：2008.4.1

  After the CB1 receptor antagonist SR141716 (rimonabant) was previously reported to modulate food intake, CB1 antagonism has been considered as a new therapeutic target for the treatment of obesity. Several series of urea, carbamate, amide, sulfonamide and oxalamide derivatives based on 1-benzhydrylpiperazine scaffold were synthesized and tested for CB1 receptor binding affinity. The SAR studies to optimize the CB1 binding affinity led to the potent urea derivatives. After the additional SAR studies to optimize the substituents of diphenyl rings, the combination of 2-chlorophenyl and 4-chlorophenyl turned out to be the most potent scaffold. The CB2 binding affinity assay as well as functional assay was also conducted on these compounds. Herein we wish to introduce several novel CB1 antagonists with IC50 values less than 100 nM for the CB1 receptor binding. (C) 2008 Elsevier Ltd. All rights reserved.